SCHEMBL6895296

SCHEMBL6895296

COc1ccc(-c2ccc3[nH]c(C4CCN(C(=O)[C@](C)(N)Cc5cccs5)CC4)nc3c2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 4/20 0.49
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
TLR7 Q9NYK1 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TLR8 Q9NR97 3/20 0.39
TLR9 Q9NR96 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALPL P05186 1/20 0.39
ALPG P10696 1/20 0.39
PIK3CD O00329 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CG P48736 2/20 0.38
USP2 O75604 2/20 0.38
PIK3CB P42338 1/20 0.38
MAPK1 P28482 1/20 0.38
PDE10A Q9Y233 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1983514 0.85 HTR2B (0.50) HTR2BLMNATP53MAPTHTT
SCHEMBL1983513 0.85 HTR2B (0.50) HTR2BLMNATP53MAPTHTT
SCHEMBL1982924 0.81 HTR2B (0.46) HTR2BLMNATP53MAPTHTT
SCHEMBL1982922 0.81 HTR2B (0.46) HTR2BLMNATP53MAPTHTT
SCHEMBL1981326 0.72 DPP4 (0.42) HTR2BLMNATLR7SMN1; SMN2TLR8
SCHEMBL1981327 0.72 DPP4 (0.42) HTR2BLMNATLR7SMN1; SMN2TLR8
SCHEMBL1299684 0.72 HTR2B (0.79) HTR2BSMN1; SMN2ALDH1A1USP2PDE10A
SCHEMBL27878469 0.70 TLR7 (0.37) LMNATLR7SMN1; SMN2TLR8TLR9
SCHEMBL27878467 0.70 TLR7 (0.37) HTR2BLMNAMAPTTLR7SMN1; SMN2
SCHEMBL1980560 0.69 CTSS (0.41) LMNATLR7SMN1; SMN2TLR8TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011075634-A1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 WO disclosed